Citations

Clear

3310 citation(s) found for "Do, Alexander".

Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.
Venn, Oliver, Aravanis, Alex, Maddala, Tara, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Yeatman, Timothy J. , Seiden, Michael V., Oxnard, Geoffrey R. , Liu, Minetta C. , Williams, Richard T. , Hartman, Anne‐Renee , Baselga, José , Swanton, Charles , Aravanis, Alexander M. , Hubbell, Earl , Gross, Samuel, Zhang, Nan , Bolton, Kelly L.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 12003-12003

10.1200/jco.2018.36.15_suppl.12003 Get It

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).
Chen, Robert W., Ansell, Stephen M. , Gallamini, Andrea , Grigg, Andrew , Sureda, Anna M., Feldman, Tatyana , Özdemir, Evren , Offner, Fritz , Engley, Gerald, Fenton, Keenan , Lee, Shih-Yuan, Jolin, Hina, Gautam, Ashish , Hutchings, Martin , Connors, Joseph M. , Savage, Kerry J. , Collins, Graham P. , Sureda, Anna , Ghosh, Nilanjan , Fosså, Alexander

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7539-7539

10.1200/jco.2018.36.15_suppl.7539 Get It

Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial.
Kommoss, Stefan , Winterhoff, Boris , Aliferis, Constantin , Burges, Alexander , Canzler, Ulrich , Wang, Jinhua , Belau, Antje , Hanker, Lars , Ma, Sisi , Hilpert, Felix , Tourani, Roshan , Kimmig, Rainer , Kurzeder, Christian , Schmalfeldt, Barbara , Dowdy, Sean C. , Pfisterer, Jacobus , Heitz, Florian , Wang, Chen , Ma, Sisi , Sehouli, Jalid , Bois, Andreas du

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5550-5550

10.1200/jco.2018.36.15_suppl.5550 Get It

ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.
Dubuc, Adrian M. , Gaffey, Sarah, Gedulig, Jack E., Ramkissoon, Shakti, Groot, John Frederick De, Welch, Mary , Schiff, David , Ahluwalia, Manmeet S. , Colman, Howard , Wen, Patrick Y. , Ahluwalia, Manmeet S , Touat, Mehdi , Meredith, David M. , Galanis, Evanthia , Nabors, Burt , Arrillaga, Isabel, Chiocca, E Antonio , Santagata, Sandro , Colman, Howard , Drappatz, Jan , Alexander, Brian M. , Wen, Patrick Yung , Ligon, Keith L

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2003-2003

10.1200/jco.2018.36.15_suppl.2003 Get It

Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Plummer, Elizabeth Ruth, Cook, Natalie , Melear, Jason M., Redfern, Charles H., Chung, Ki Y. , Haddad, Tufia C. , Goddemeier, Thomas, Arkenau, Hendrik‐Tobias , Spira, Alexander I. , Shapiro, Geoffrey I. , Ramalingam, Suresh S. , Wesolowski, Robert , Falk, Martin H., Dean, Emma

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e21048-e21048

10.1200/jco.2018.36.15_suppl.e21048 Get It

A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.
Foster, Nathan R. , Zoroufy, Alexander J., Souza, Jonas A. de, Jelinek, Michael J. , Schwartz, Gary K. , Münster, Pamela N. , Seiwert, Tanguy Y. , Vokes, Everett E.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 6031-6031

10.1200/jco.2018.36.15_suppl.6031 Get It

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Barry, William T., Wenham, Robert M. , Hendrickson, Andrea E. Wahner , Armstrong, Deborah K. , Chan, Nancy , Lee, Jung‐Min , Penson, Richard T. , Cristea, Mihaela , Abbruzzese, James L. , Matsuo, Koji , Olawaiye, Alexander , Farooq, Sarah , Kohn, Elise C. , Matulonis, Ursula A. , Liu, Joyce F. , Cohn, David E. , Swisher, Elizabeth M. , Van Allen, Eliezer M , Shapiro, Geoffrey I. , Ivy, S. Percy

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5519-5519

10.1200/jco.2018.36.15_suppl.5519 Get It

Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).
Starodub, Alexander, El‐Rayes, Bassel F. , Shahda, Safi, O’Neil, Bert H. , Shaib, Walid L. , Hanna, Wahid T., Mikhail, Sameh , Neki, A., Chang, Yue , Dai, Xiaoshu, Li, Wei , Brooks, Emily , Oh, Cindy , Borodyansky, Laura, Li, Chiang, El-Rayes, Bassel F , Bekaii‐Saab, Tanios , Noonan, Anne M. , Brooks, Emily

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4110-4110

10.1200/jco.2018.36.15_suppl.4110 Get It

Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.
Liu, Minetta C. , Maddala, Tara, Aravanis, Alex, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Venn, Oliver, Smith, David A. , Curtis, Christina , Williams, Richard T. , Hartman, Anne‐Renee , Baselga, José, Aravanis, Alexander M. , Hubbell, Earl , Gross, Samuel, Kurtzman, Kathryn N. , Zhang, Nan , Couch, Fergus J. , Klein, Eric A.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 536-536

10.1200/jco.2018.36.15_suppl.536 Get It